Skip to main content
Premium Trial:

Request an Annual Quote

BGI Coronavirus Molecular Diagnostic Test Garners CE Mark

NEW YORK – BGI said late on Friday that its Real-Time Fluorescent RT-PCR kit for detecting SARS-CoV-2 (also known as 2019-nCoV) has received CE-IVD marking and is now commercially available in markets recognizing the designation.

BGI's kit is a qualitative in vitro nucleic acid amplification assay that detects 2019-mCoV, the cause of COVID-19, using reverse transcriptase PCR from throat swab and bronchoalveolar lavage fluid samples.

The CE-IVD mark follows approval by China's National Medical Products Administration in late January of BGI's PCR kit and BGI subsidiary MGI's full sequencing platform and metagenomic sequencing assay for SARS-CoV-2 detection.

BGI said the PCR assay is already widely used in China for diagnosing suspected cases and determining whether recovered patients should be discharged. The Huo-Yan Laboratory in Wuhan, the emergency test laboratory run by BGI, is designed to handle 10,000 samples daily using the kits daily, the company said.

The Scan

Sensor to Spot SARS-CoV-2 Exposure

Yale researchers have developed a sensor that gauges SARS-CoV-2 exposure, according to the New Haven Register.

Watching BA.2

A subtype of the Omicron SARS-CoV-2 variant has been found in a number of countries, the Washington Post says.

Vermont Weighs Genetic Discrimination Bill

VT Digger reports Vermont legislators are considering a bill to bar insurer from denying customers coverage based on genetic information.

PNAS Papers on Convergent Pathogen Effectors, Lineage-Related RNA Mutations, Desiccation-Tolerant Grass

In PNAS this week: convergent evolution of pathogen effectors, algorithm to identify cell lineage features, and more.